Tissue microarrays (TMAs) for high-throughput molecular pathology research

被引:194
作者
Nocito, A
Kononen, J
Kallioniemi, OP
Sauter, G
机构
[1] Univ Basel, Inst Pathol, Basel, Switzerland
[2] Univ Tampere, Tampere Univ Hosp, Canc Genet Lab, FIN-33101 Tampere, Finland
[3] NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA
关键词
tissue microarrays; high throughput; pathology; immunohistochemistry; prognostic markers;
D O I
10.1002/ijc.1385
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A rapidly increasing number of genes are being suspected to play a role in cancer biology. To evaluate the clinical significance of newly detected potential cancer genes, it is usually required to examine a high number of well-characterized primary tumors. Using traditional methods of molecular pathology, this is a time consuming endeavor rapidly exhausting precious tissue resources. To allow for a high throughput tissue analysis we have developed a "tissue chip" approach (Kononen et al., Nat. Med. 1998;4:844-7). Using this tissue microarray (TMA) technology, samples from up to 1,000 different tumors are arrayed in one recipient paraffin block, sections of which can be used for all kind of in situ analyses. Sections from TMA blocks can then be utilized for the simultaneous analysis of up to 1,000 different tumors on the DNA, RNA or protein level. TMAs allow a high through-put molecular analysis of thousands of tumors within a few burs. All currently available data have suggested that minute arrayed tissue specimens are highly representative of their donor tissues. There are multiple different types of TMAs that can be utilized in cancer research including multi tumor arrays (containing different tumor types), tumor progression arrays (tumors of different stages) and prognostic arrays (tumors with clinical endpoints). The combination of multiple different TMAs allows a very quick but comprehensive characterization of biomarkers of interest. We anticipate that the use of TMAs will greatly accelerate the transition of basic research findings to clinical applications. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:1 / 5
页数:5
相关论文
共 18 条
  • [1] Ayers LW, 2000, J ACQ IMMUN DEF SYND, V23, pA18
  • [2] Bärlund M, 2000, CANCER RES, V60, P5340
  • [3] Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis
    Bärlund, M
    Forozan, F
    Kononen, J
    Bubendorf, L
    Chen, YD
    Bittner, ML
    Torhorst, J
    Haas, P
    Bucher, C
    Sauter, G
    Kallioniemi, OP
    Kallioniemi, A
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (15) : 1252 - 1259
  • [4] BATTIFORA H, 1986, LAB INVEST, V55, P244
  • [5] Hormone therapy failure in human prostate cancer:: Analysis by complementary DNA and issue microarrays
    Bubendorf, L
    Kolmer, M
    Kononen, J
    Koivisto, P
    Mousses, S
    Chen, YD
    Mahlamäki, E
    Schraml, P
    Moch, H
    Willi, N
    Elkahloun, AG
    Pretlow, TG
    Gasser, TC
    Mihatsch, MJ
    Sauter, G
    Kallioniemi, OP
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (20) : 1758 - 1764
  • [6] Bubendorf L, 1999, CANCER RES, V59, P803
  • [7] Bucher C, 1999, AM J HUM GENET, V65, pA10
  • [8] BUCHER C, 2000, 36 ANN M AM SOC CLIN
  • [9] DeRisi J, 1996, NAT GENET, V14, P457
  • [10] Expression profiling using cDNA microarrays
    Duggan, DJ
    Bittner, M
    Chen, YD
    Meltzer, P
    Trent, JM
    [J]. NATURE GENETICS, 1999, 21 (Suppl 1) : 10 - 14